Tenax Therapeutics, Inc.
TENX
$5.80
$0.030.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.79M | 5.73M | 5.27M | 4.96M | 5.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.49M | 15.54M | 13.04M | 10.60M | 8.23M |
| Operating Income | -19.49M | -15.54M | -13.04M | -10.60M | -8.23M |
| Income Before Tax | -17.60M | -14.56M | -12.57M | -10.10M | -7.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.60 | -14.56 | -12.57 | -10.10 | -7.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.60M | -14.56M | -12.57M | -10.10M | -7.71M |
| EBIT | -19.49M | -15.54M | -13.04M | -10.60M | -8.23M |
| EBITDA | -19.49M | -15.53M | -13.03M | -10.59M | -8.23M |
| EPS Basic | -5.31 | -15.92 | -22.35 | -24.52 | -33.51 |
| Normalized Basic EPS | -3.32 | -9.96 | -13.97 | -15.33 | -20.93 |
| EPS Diluted | -5.31 | -15.92 | -22.35 | -24.52 | -33.51 |
| Normalized Diluted EPS | -3.32 | -9.96 | -13.97 | -15.33 | -20.93 |
| Average Basic Shares Outstanding | 59.63M | 24.64M | 3.77M | 2.09M | 989.90K |
| Average Diluted Shares Outstanding | 59.63M | 24.64M | 3.77M | 2.09M | 989.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |